全球结节性淋巴细胞为主型霍奇金淋巴瘤一个工作组（GLOW）的结节性淋巴细胞为主型霍奇金淋巴瘤研究路线图。
Global nLPHL One Working Group (GLOW) Research Roadmap for Nodular Lymphocyte-Predominant Hodgkin Lymphoma.
作者信息
Palese Monica, Advani Ranjana H, Biney-Amissah Dominic, Birz Suzi, Collins Graham P, Hoppe Richard T, Kelly Kara M, Page-Kirby Caroline, Binkley Michael S, Flerlage Jamie E
机构信息
Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Rochester Medical Center, Rochester, New York, USA.
Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford University, Stanford, California, USA.
出版信息
Pediatr Blood Cancer. 2025 Jun;72(6):e31646. doi: 10.1002/pbc.31646. Epub 2025 Mar 9.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare, indolent lymphoma lacking an evidence-based standard of care. NLPHL research has been challenging due to its classification, unique features, and rarity. The Global nLPHL One Working Group (GLOW) launched in 2020 to accelerate NLPHL research internationally across all ages and stages and to establish a global standard of care. GLOW identified six core aims and 19 activities in its strategic roadmap to overcome historical research challenges, establish a research pipeline to inform a global standard of care, and disseminate findings. Once its prospective trials launch, GLOW will leverage this roadmap to study other rare lymphomas.
结节性淋巴细胞为主型霍奇金淋巴瘤（NLPHL）是一种罕见的惰性淋巴瘤，目前缺乏基于证据的标准治疗方案。由于其分类、独特特征和罕见性，NLPHL的研究一直具有挑战性。全球NLPHL一号工作组（GLOW）于2020年成立，旨在加速全球范围内各年龄和阶段的NLPHL研究，并建立全球标准治疗方案。GLOW在其战略路线图中确定了六个核心目标和19项活动，以克服历史研究挑战，建立研究渠道以为全球标准治疗方案提供依据，并传播研究结果。一旦其前瞻性试验启动，GLOW将利用该路线图研究其他罕见淋巴瘤。
Zotero 插件